We are live on ! Find out more
PRTK

Paratek Pharmaceuticals, Inc.

Delisted

PRTK was delisted on the 20th of September, 2023.

133 hedge funds and large institutions have $609M invested in Paratek Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 48 increasing their positions, 33 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 20

64% more call options, than puts

Call options by funds: $8.47M | Put options by funds: $5.15M

45% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 33

12% more funds holding

Funds holding: 119133 (+14)

8% more capital invested

Capital invested by funds: $564M → $609M (+$45.4M)

50% less funds holding in top 10

Funds holding in top 10: 63 (-3)

Holders
133
Holders Change
+14
Holders Change %
+11.76%
% of All Funds
3.32%
Holding in Top 10
3
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-50%
% of All Funds
0.07%
New
34
Increased
48
Reduced
33
Closed
20
Calls
$8.47M
Puts
$5.15M
Net Calls
+$3.32M
Net Calls Change
-$919K
Name Holding Trade Value Shares
Change
Change in
Stake
Allianz Asset Management
51
Allianz Asset Management
Germany
$1.64M +$86.6K +3,719 +6%
TCIM
52
TIAA CREF Investment Management
New York
$1.6M -$678K -29,132 -31%
EIM
53
Essex Investment Management
Massachusetts
$1.57M +$565K +24,267 +63%
PPA
54
Parametric Portfolio Associates
Washington
$1.34M -$440K -18,916 -26%
AI
55
Axiom Investors
Connecticut
$1.25M -$329K -14,130 -22%
PAM
56
Panagora Asset Management
Massachusetts
$1.24M +$1.15M +49,195 New
GC
57
Guggenheim Capital
Illinois
$1.22M -$191K -8,218 -14%
HCMT
58
Highland Capital Management (Texas)
Texas
$1.21M +$1.12M +48,100 New
Marshall Wace
59
Marshall Wace
United Kingdom
$1.1M +$111K +4,749 +12%
TA
60
Teachers Advisors
New York
$1.08M +$9.73K +418 +1%
MAP
61
Moody Aldrich Partners
Massachusetts
$1.08M +$1M +43,070 New
FPF
62
FNY Partners Fund
New York
$1.02M +$947K +40,700 New
OPPM
63
Opus Point Partners Management
New York
$1M
LPL Financial
64
LPL Financial
California
$990K +$237K +10,200 +35%
CS
65
Credit Suisse
Switzerland
$956K +$544K +23,387 +159%
California State Teachers Retirement System (CalSTRS)
66
California State Teachers Retirement System (CalSTRS)
California
$951K -$89.2K -3,833 -9%
Simplex Trading
67
Simplex Trading
Illinois
$911K +$275K +11,826 +48%
Federated Hermes
68
Federated Hermes
Pennsylvania
$889K +$825K +35,428 New
WMSA
69
Weiss Multi-Strategy Advisers
New York
$879K +$349K +15,000 +75%
IHM
70
Iguana Healthcare Management
New York
$879K +$815K +35,000 New
PP
71
Paloma Partners
Connecticut
$876K -$25.4K -1,093 -3%
Swiss National Bank
72
Swiss National Bank
Switzerland
$866K +$102K +4,400 +15%
Victory Capital Management
73
Victory Capital Management
Texas
$793K -$15.8K -680 -2%
New York State Common Retirement Fund
74
New York State Common Retirement Fund
New York
$758K -$215K -9,216 -23%
Susquehanna International Group
75
Susquehanna International Group
Pennsylvania
$728K +$675K +29,009 New

PRTK Hedge Fund Activity: Q3 2017 in Review

133 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2017, worth a combined $609M — up 8.1% from $564M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new PRTK positions and 20 closed out — a net gain of 14 holders — while 48 added to existing stakes and 33 trimmed.

The largest buyer was Alyeska Investment Group, adding an estimated $17.6M. The largest seller was Tekla Capital Management, exiting entirely with an estimated $12.8M sold.

  • 133 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2017, up from 119 in Q2 2017.
  • Funds reported $609M of Paratek Pharmaceuticals, Inc. stock for Q3 2017, up 8.1% quarter-over-quarter.
  • 34 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2017 and 20 closed out, a net change of +14 holders.
  • The largest Paratek Pharmaceuticals, Inc. buyer in Q3 2017 was Alyeska Investment Group, an estimated $17.6M added.
  • The largest Paratek Pharmaceuticals, Inc. seller in Q3 2017 was Tekla Capital Management, an estimated $12.8M sold.

Based on aggregated 13F filings for Q3 2017.